YP2A Stock Overview
A commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BioLineRx Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.47 |
| 52 Week High | ₪2.38 |
| 52 Week Low | ₪0.47 |
| Beta | 0.93 |
| 11 Month Change | -22.93% |
| 3 Month Change | -52.60% |
| 1 Year Change | -67.31% |
| 33 Year Change | -79.74% |
| 5 Year Change | -89.81% |
| Change since IPO | -98.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| YP2A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.1% | 0.6% | 0.09% |
| 1Y | -67.3% | -18.6% | 3.1% |
Return vs Industry: YP2A underperformed the German Biotechs industry which returned -16.6% over the past year.
Return vs Market: YP2A underperformed the German Market which returned 3% over the past year.
Price Volatility
| YP2A volatility | |
|---|---|
| YP2A Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: YP2A's share price has been volatile over the past 3 months.
Volatility Over Time: YP2A's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 79 | Phil Serlin | www.biolinerx.com |
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.
BioLineRx Ltd. Fundamentals Summary
| YP2A fundamental statistics | |
|---|---|
| Market cap | €45.62m |
| Earnings (TTM) | -€45.90m |
| Revenue (TTM) | €10.88m |
4.2x
P/S Ratio-1.0x
P/E RatioIs YP2A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YP2A income statement (TTM) | |
|---|---|
| Revenue | US$11.66m |
| Cost of Revenue | US$5.15m |
| Gross Profit | US$6.51m |
| Other Expenses | US$55.66m |
| Earnings | -US$49.15m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.041 |
| Gross Margin | 55.84% |
| Net Profit Margin | -421.69% |
| Debt/Equity Ratio | 73.6% |
How did YP2A perform over the long term?
See historical performance and comparison